公开(公告)号：US20230340008A1

公开(公告)日：2023-10-26

申请号：US17791799

申请日：2021-02-18

Applicant: Osaka University ,  Japan Represented by Director General of National Institute of Health Sciences

Inventor： Satoshi OBIKA ,  Takao YAMAGUCHI ,  Hibiki KOMINE ,  Takaya SUGIURA ,  Takao INOUE ,  Tokuyuki YOSHIDA

IPC: C07H21/02

CPC classification number: C07H21/02

Abstract: Disclosed are a bridged nucleoside and a nucleotide using the same. The nucleoside of the present invention is represented by the formula (I) below. The bridged nucleoside of the present invention is usable as a substitute for a phosphorothioate-modified nucleic acid, which has a risk of, for example, accumulation in a specific organ. The bridged nucleoside also has excellent industrial productivity.

公开(公告)号：US20170044528A1

公开(公告)日：2017-02-16

申请号：US15118546

申请日：2015-02-17

Applicant: OSAKA UNIVERSITY

Inventor： Satoshi OBIKA ,  Takao YAMAGUCHI ,  Masahiko HORIBA ,  Reiko WAKI

IPC: C12N15/113 ,  C07H19/16 ,  C07H19/06

CPC classification number: C12N15/113 ,  C07H19/06 ,  C07H19/16 ,  C07H21/00 ,  C12N2310/31

Abstract: Disclosed are bridged nucleosides and nucleotides. The nucleosides of the present invention have a 2′,4′-bridged structure and are represented by formula I below: An oligonucleotide containing a 2′,4′-bridged artificial nucleotide of the present invention has a binding affinity for single-stranded RNA comparable to that of known 2′,4′-BNA/LNA and higher nuclease resistance than LNA. In particular, since the oligonucleotide has a much higher binding affinity for single-stranded RNA than S-oligo, it is expected that the oligonucleotide is applicable to nucleic acid drugs.

Abstract translation: 含有本发明的2'，4'-桥接人造核苷酸的寡核苷酸对于单链RNA具有与已知的2'，4'-BNA / LNA和比NNA更高的核酸酶抗性相当的结合亲和力。 特别是，由于寡核苷酸对单链RNA的结合亲和力高于S-寡聚体，所以预期该寡核苷酸适用于核酸药物。

公开(公告)号：US20220177509A1

公开(公告)日：2022-06-09

申请号：US17601326

申请日：2020-03-31

Applicant: NIPPON SHOKUBAI CO., LTD. ,  OSAKA UNIVERSITY

Inventor： Takeshi BABA ,  Hiroshi OKAMOTO ,  Yumi NOMURA ,  Satoshi OBIKA ,  Takao YAMAGUCHI

IPC: C07H19/16 ,  C07H19/06 ,  C07H1/00

Abstract: Provided is a method for producing a compound represented by formula (III) from a compound represented by formula (I) as a starting material.

公开(公告)号：US20220127300A1

公开(公告)日：2022-04-28

申请号：US17428998

申请日：2020-02-10

Applicant: Osaka University

Inventor： Satoshi OBIKA ,  Takao YAMAGUCHI ,  Takaki HABUCHI ,  Go KATO ,  Takao INOUE ,  Tokuyuki YOSHIDA ,  Md Ariful ISLAM

IPC: C07H21/04

Abstract: Disclosed are a 5′-modified nucleoside and a nucleotide using the same. The nucleoside of the present invention is represented by the formula (I) below. The 5′-modified nucleoside of the present invention is usable as a substitute for a phosphorothioate-modified nucleic acid, which has a risk of, for example, accumulation in a specific organ. The 5′-modified nucleoside also has excellent industrial productivity because a diastereomer separation step is not involved in the production process thereof.

公开(公告)号：US20240409919A1

公开(公告)日：2024-12-12

申请号：US18733430

申请日：2024-06-04

Applicant: SHIMADZU CORPORATION ,  OSAKA UNIVERSITY

Inventor： Satoshi OBIKA ,  Takao YAMAGUCHI ,  Momoka HAYASHIDA ,  Junichi MASUDA ,  Shinosuke HORIE ,  Risa SUZUKI

IPC: C12N15/10 ,  B01D15/40

Abstract: A method for separating components using a supercritical fluid chromatograph, including: injecting a sample into a mobile phase containing a supercritical fluid and a modifier to introduce the sample into a column; and separating components in the sample during passing through the column; wherein the sample contains an oligonucleotide as a target component; the supercritical fluid contains carbon dioxide; and the modifier contains a solution containing at least one selected from the group consisting of ammonium, an alkylamine, and an amino alcohol, and an acid.

公开(公告)号：US20220372060A1

公开(公告)日：2022-11-24

申请号：US17427134

申请日：2020-01-31

Applicant: Osaka University

Inventor： Satoshi OBIKA ,  Takao YAMAGUCHI ,  Takaki HABUCHI ,  Go KATO ,  Takao INOUE ,  Tokuyuki YOSHIDA ,  Takaya SUGIURA

IPC: C07H19/10 ,  C07H19/20 ,  C07H21/00

Abstract: Disclosed are a 5′-modified nucleoside and a nucleotide using the same. The nucleoside of the present invention is represented by the formula (I) below. The 5′-modified nucleoside of the present invention is usable as a substitute for a phosphorothioate-modified nucleic acid, which has a risk of, for example, accumulation in a specific organ. The 5′-modified nucleoside also has excellent industrial productivity because a diastereomer separation step is not involved in the production process thereof.

公开(公告)号：US20230124641A1

公开(公告)日：2023-04-20

申请号：US17800339

申请日：2021-02-17

Applicant: Osaka University ,  Japan as Represented by Director General of National Institute of health Sciences

Inventor： Satoshi OBIKA ,  Takao YAMAGUCHI ,  Yota SAKURAI ,  Chika YAMAMOTO ,  Kei SUGITA ,  Takao INOUE ,  Tokuyuki YOSHIDA

IPC: C07D493/08 ,  C07H21/04 ,  C07D239/10

Abstract: A cross-linked nucleoside of the present invention is a compound represented by the formula (I) below. The cross-linked nucleoside of the present invention is usable as a substitute for a phosphorothioate-modified nucleic acid, which has a risk of, for example, accumulation in a specific organ. The cross-linked nucleoside also has excellent industrial productivity.